Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 19, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 750,000 ordinary shares of 25 pence each.
- Purchase Price: 1,310.43 pence per share.
- Treasury Holdings: Following the purchase, the company holds 317,239,158 shares in Treasury.
- Treasury Percentage: Treasury shares represent 5.56% of total voting rights.
- Shares in Issue: 5,703,496,370 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the acquisition of 750,000 shares for Treasury. Consequently, the total number of shares held in Treasury increased to 317,239,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the 750,000 share repurchase based on the disclosed price of 1,310.43 pence per share.
- Confirm the updated total voting rights denominator (5,703,496,370 shares) for calculating disclosure thresholds under FSA rules.
- Note that the company intends to hold the repurchased shares in Treasury rather than canceling them immediately.
- Recognize that this filing does not contain operational or financial performance data for the period.